Assembly Biosciences Inc (ASMB) Q1 2015 10-Q Quarterly Earnings

Short answer

Assembly Biosciences Inc (ASMB) filed its Q1 2015 10-Q quarterly report on May 8, 2015 for the quarter ended Mar 31, 2015.

AI summary of MD&A and risk factor updates

Revenue $0, no product sales in either quarter
Operating loss $7,144,953, versus undisclosed prior-year figure
HBV research expense $2,051,331, exceeding Microbiome expense of $727,670
Operating cash use $3,673,353, financing cash provided $70,677,033
Net offering proceeds approximately $70.5 million, cash sufficient for at least twelve months

No material risk-factor changes from the 2014 Form 10-K
Regulatory risk: no product revenue until FDA or foreign regulatory approval
Operational risk: continued development losses and no approved products, accumulated deficit $142,657,025
Financial risk: existing cash expected to fund operations at least twelve months, but additional financing remains necessary
Capital-markets risk: future equity financing could dilute stockholders or debt financing could impose restrictive covenants

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Compare quarters, check guidance or see what insiders and funds did around the report.